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Knowledge of the immunological correlates of Staphylococcus aureus and Streptococcus pneumoniae colonization is required for
the search for future protein vaccines. We evaluated natural antibody levels against pneumococcal and staphylococcal proteins
in relation to previous bacterial colonization with both pathogens. In a randomized controlled trial, nasopharyngeal samples
were obtained from children at 1.5, 6, 12, 18, and 24 months and cultured for S. aureus and S. pneumoniae. Approximately 50%
of the children were PCV7 vaccinated. Serum IgG against 18 pneumococcal and 40 staphylococcal proteins was semiquantified
by Luminex technology from 111 12 month olds and 158 24 month olds. Previous culture-proven S. aureus colonization was
associated with higher IgG levels against 6/40 staphylococcal proteins (ClfB, ClfA, Efb, CHIPS, LukD, and LukF [P< 0.001])
compared to noncarriers. Previous pneumococcal colonization was associated with increased IgG levels against 12/18 pneumo-
coccal proteins compared to noncarriers (P< 0.003). Increasing age was associated with higher levels of antibodies to most
pneumococcal proteins and lower levels of antibodies to over half the staphylococcal proteins, reflecting natural colonization
dynamics. Anti-S. pneumoniae and anti-S. aureus protein antibodies at the age of 12 months were not negatively correlated with
subsequent colonization with the homologous species in the following year and did not differ between PCV7-vaccinated and
nonvaccinated children. Colonization with S. aureus and S. pneumoniae induces serum IgG against many proteins, predomi-
nantly proteins with immune-modulating functions, irrespective of PCV7 vaccination. None of them appeared to be protective
against new acquisition with both pathogens, possibly due to the polymorphic nature of those proteins in the circulating bacte-
rial population.
Streptococcus pneumoniae and Staphylococcus aureus are bothimportant causes of bacterial infections in children in the first
years of life (14, 21).Nasopharyngeal colonization is a prerequisite
for the development of diseases. Preventive strategies may aim for
protection against acquisition and colonization or subsequent in-
fection. Current pneumococcal conjugate vaccines are based on
the capsule as antigen and therefore restricted to the present epi-
demiologically predominant capsular serotypes in children (11).
Although the 7-valent pneumococcal conjugate vaccine (PCV7)
has been shown to effectively eradicate the vaccine serotype pneu-
mococci from the nasopharynx, the vacant niche is immediately
filled by nonvaccine pneumococci, which may also cause disease
(7, 35). For this reason, there has been growing interest in vaccines
against common and conserved pneumococcal proteins, since
they may target all pneumococcal strains irrespective of capsule
(32). Inmice, immunizationwith pneumococcal proteins, such as
the pneumococcal histidine triad (Pht) proteins, as well as PspA,
PdbD, PmpA, CbpA (PspC), and PsaA, has been proven effective
against pneumococcal colonization or invasive disease (3, 11, 25,
26, 32).
Comparable strategies are needed to prevent S. aureus coloni-
zation and infection, wheremultidrug (methicillin) resistance has
become a serious problem (19). Several S. aureus proteins, e.g.,
clumping factor A (ClfA), clumping factor B (ClfB), and IsdB,
have been shown to protect against colonization and invasive dis-
ease in mice (13, 24, 39).
To predict which proteins might be of special interest to pre-
vent disease in humans, we investigated the dynamics, immuno-
genicity, and (cross)protectiveness of virulence proteins of both
species in relation to nasopharyngeal colonization. In a random-
ized controlled trial (RCT) setting, we determined IgG levels
against 18 pneumococcal and 40 S. aureus virulence factors, which
included 21 newly tested S. aureus proteins.
These antibody levelswere all examined in relation to nasopha-
ryngeal colonization andPCV7 vaccination by Luminexmultiplex
technology.
MATERIALS AND METHODS
Design, sample collection, and processing. Between July 2005 and Feb-
ruary 2006, before nationwide implementation of PCV7, 1,003 infants
were enrolled in a randomized controlled trial, investigating the effects of
reduced-dose PCV7 schedules on pneumococcal colonization during the
Received 12 January 2012 Returned for modification 12 February 2012
Accepted 5 March 2012
Published ahead of print 9 April 2012
Editor: A. Camilli
Address correspondence to Debby Bogaert, d.bogaert@umcutrecht.nl.
Supplemental material for this article may be found at http://iai.asm.org.
Copyright © 2012, American Society for Microbiology. All Rights Reserved.
doi:10.1128/IAI.00037-12
2186 iai.asm.org Infection and Immunity p. 2186–2193 June 2012 Volume 80 Number 6
 o
n
 April 30, 2018 by guest
http://iai.asm
.org/
D
ow
nloaded from
 
first 2 years of life (NCT00189020) (35). In brief, after obtaining written
informed consent from both parents or a guardian, healthy participants
were randomly assigned to receive PCV7 (i) PCV7 at 2 and 4 months of
age (2-dose group); (ii) PCV7 at 2, 4, and 11months (2- 1-dose group);
or (3) no PCV7 (control group). Part of this cohort was asked to partici-
pate in the immunogenicity arm of the study on a voluntary basis (for
details, see reference 31). The present study was performed in the 2- 
1-dose (n 116) and control (n 91) groups (baseline characteristics are
shown in Table 1).
During house visits, 269 serum samples, 111 samples from 12 month
olds, and 158 samples from 24 month olds, including 62 consecutive se-
rum samples, were collected. Serawere separatedwithin 24 h and stored at
20°C until they were assayed. For each child, swabs were obtained by
approaching the nasopharynx transnasally at 6 weeks and 6, 12, 18, and 24
months of age with a flexible, dry cotton-wool swab. Transport, isolation,
and identification of pneumococci and S. aureus in these 1,013 samples
were done using standard methods (35, 36). A national ethics committee
from The Netherlands approved the trial. The study was performed in
accordance with the European Statements for Good Clinical Practice.
Detection of anti-protein antibodies. Antibodies to pneumococcal
and S. aureusproteinsweremeasured in serumby amultiplex fluorescent-
bead-based immunoassay (xMap; Luminex). This is a validated technique
for both protein panels (34, 37), where validation was repeated upon
expansion of the panels, as well. We confirmed for IgG directed against
TSST-1 that there is a correlation between median fluorescence intensity
(MFI) values and the in vitro neutralizing capacity of antibodies (37). The
antigens used in this study were selected based on (i) immunological
importance, as indicated by the current scientific literature; (ii) their po-
tential role in vaccine development; and (iii) availability (2, 6, 9, 10, 23, 29,
33, 34, 37). Isolation, purification, coupling of the antigens and determi-
nation of IgG antibodies by Luminex were performed as described previ-
ously (34, 37). In each experiment, control beads (not protein coupled)
were included to determine nonspecific antibody binding. In case of non-
specific binding, these MFI values were subtracted from the antigen-spe-
cific values.We used human pooled sers (HPS) from 36 healthy donors as
a standard tool to test for interassay variation. Tests were accomplished as
independent duplicates. The MFI values represent antibody levels in a
semiquantitative way. Since MFIs are not normally distributed, we aver-
aged and log transformed them.
All MFI values above zero were defined as measurable antibody titers.
Abbreviations of all tested S. aureus and S. pneumoniae virulence factors
are listed in Table S1 in the supplemental material. IgG levels against 18
pneumococcal antigens were determined: toxins PLY and PdbD, which is
a double mutant of PLY; pneumococcal cell surface proteins CbpA
(PspC), PspA, PpmA, SlrA, PsaA, Hyl, NanA, BvH-3, Pht-D (Sp1003;
BVH-11-2; histidine triad protein), and Pilus A; enzymes ENO and IgA-1;
and proteins Sp0189 (hypothetical protein), Sp0376 (response regulator;
intracellular location), Sp1633 (response regulator; intracellular loca-
tion), and Sp1651 (thiol peroxidase; intracellular location) (15, 18, 23).
The data on the double mutant, PdbD are not shown, since children are
not exposed to this protein in nature. In addition, IgG levels against 40 S.
aureus antigens were determined: the microbial surface components rec-
ognizing adhesive matrix molecules (MSCRAMMs) ClfA, ClfB, SasG,
IsdA, IsdH, FnbpA, FnbpB, SdrD, and SdrE; staphylococcal enterotoxins
(SE) SEA to SEE, SEG to SEJ, SEM to SEO, SEQ, and SER; and staphylo-
coccal superantigen-like 1 (SSL-1), SSL-3, -5, -9, and -11 and TSST-1;
exfoliative toxins ETA and ETB; leukocidins LukD, LukE, LukF, and
LukS; alpha-toxin; HlgB; and immunomodulatory proteins SCIN, che-
motaxis inhibitory protein (CHIPS), and extracellular fibrinogen binding
protein (Efb) (39).
Outcomemeasures.The immunogenicity of proteins was analyzed by
studying the correlation between antibody levels at 12 months of age and
colonization in the previous year (measured as culture positive at the age
of 6 weeks and/or 6 months) and the correlation between antibody levels
at the age of 24months and colonization in the previous year (measured as
culture positive at 12 and/or 18 months of age) and in the whole previous
period of 2 years.
To reflect general protein antibody responses to each organism, we
performed a combinedmeasurement. First, for each age group, titers were
ranked for each protein (from low to high MFI), followed by a combined
ranking for all pneumococcal or staphylococcal protein responses per
child. These values were correlated with previous colonization status.
The potential protectiveness of anti-protein antibodies was studied by
correlating antibody levels at 12 months of age with colonization with the
homologous species in the following year (as measured at the age of 18
and/or 24 months).
Statistical analysis.Mann-Whitney U tests were used to study immu-
nogenicity, overall “species” antibody responses, potential protectiveness,
and PCV7 vaccine effects. Wilcoxon signed rank tests were used to study
the dynamics of antibodies in time for children for whom we had paired
samples available. Antibody levels were determined as continuous vari-
ables. Kruskall-Wallis tests were used to test the impact of colonization
frequency.
For all analysis, a Bonferroni correction was applied to adjust for
multiple comparisons. In this study, we tested 40 S. aureus and 18 pneu-
mococcal proteins; therefore, the null hypothesis was rejected for com-
parisons regarding anti-staphylococcal-protein and anti-pneumococcal-
protein antibodies with P values of0.001 and0.003, respectively. The
statistical analyses were performed using the Statistical Package of Social
Sciences version 17.0 for Windows (SPSS Inc., Chicago, IL).
RESULTS
IgG levels against 18 pneumococcal and 40 staphylococcal viru-
lence proteins were determined in 269 serum samples collected
from 111 12-month-old and 158 24-month-old children (Table
1). In the serum samples of all 12-month-old children, the IgG
levels (MFI units) against the S. aureus proteins SSL-3, SSL-9, and
Hlgb remained nonconcordant when tested in duplicate and were
consequently excluded from analyses. We excluded data on 2, 6,
and 11 samples of all S. aureus proteins (12months), pneumococ-
cal proteins (12 months), and pneumococcal proteins (24
TABLE 1 Baseline characteristics of participants receiving 2 1 doses
(PCV7) or no PCV7 vaccinations (controls)
Parameter
No. (%)
All children PCV7 Controls
Total 207 116 (56) 91 (44)
Male gender 107 (52) 60 (56) 47 (44)
Serum samples (n 269)
12 mo olds 111 82 (74) 29 (26)
24 mo olds 158 78 (49) 80 (51)
Paired 62 44 (71) 18 (30)
Nasopharynx cultures (n 1,030)a
Children culture positive for S. aureus
6 wk 96 (46) 53 (46) 43 (47)
6 mo 25 (12) 15 (13) 10 (11)
12 mob 22 (11) 15 (13) 7 (8)
18 mo 16 (8) 9 (8) 7 (8)
24 mob 17 (8) 11 (10) 6 (7)
Children culture positive for S. pneumoniae
6 wk 30 (15) 20 (17) 10 (11)
6 mo 99 (48) 56 (48) 43 (47)
12 mob 125 (66) 70 (60) 55 (60)
18 mo 132 (64) 66 (57) 66 (73)
24 mob 123 (59) 66 (57) 57 (63)
a Missing 1 and 2 cultures at 12 and 18 months, respectively.
b Culture times at which blood samples were obtained.
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months), respectively, because of nonconcordant results. There-
fore, statistical analyses are based on 105/111 (12 months) and
147/158 (24months) samples of pneumococcal proteins and 109/
111 (12 months) and 158/158 (24 months) samples of S. aureus
proteins. Consequently, of the 62 paired samples, 56 were avail-
able for anti-pneumococcal protein and 60 for anti-S. aureus pro-
tein analyses.
Natural humoral responses against S. pneumoniae and S.
aureus proteins in infancy.To study the natural immunogenicity
of S. pneumoniae and S. aureus proteins, we determined in the
paired serum samples the number of children with detectable nat-
ural antibodies against these proteins at the ages of 12 and 24
months irrespective of colonization status. In general, all anti-
pneumococcal-protein antibody titers increased between the ages
of 12 and 24 months (P 0.003), except for Sp1651. In contrast,
for over half of the S. aureus proteins (23/40), we observed a de-
crease in antibody titers between 12 and 24 months of age (P 
0.001). The other 17 anti-staphylococcal-protein antibodies re-
mained at a more or less stable level (Fig. 1). Nevertheless, at 12
months of age, we already observed inmore than three-quarters of
infants measurable antibodies against most pneumococcal pro-
teins, whereas at 24 months of age, almost all children had detect-
able antibodies against those proteins. The only exception was
observed for IgG against Pilus A antigen, which was found in only
10% of 12-month-old children, although this increased rapidly to
87% in 24 month olds. With respect to the antibody response
against S. aureus proteins, we observed antibodies directed against
all but one staphylococcal protein in almost all 12-month-old
children. However, at 24 months of age, detectable anti-protein
IgG dropped, depending on the protein measured. For more de-
tailed information regarding the dynamics of the natural humoral
responses in infancy, see Tables S2 and S3 in the supplemental
material.
Immunogenicity of S. pneumoniae and S. aureus virulence
proteins in relation to proven previous colonization in infancy.
We investigated the immunogenicities of all S. pneumoniae and S.
aureus proteins in relation to recent challenge with the homolo-
gous species, defined as culture-proven carriage at the preceding
two sample times.
In children with proven challenge at the age of 6 weeks and/or
6 months or at 12 and/or 18 months of age, the levels of IgG
against the proteins PLY, PdbD, CbpA (PspC), PspA, PpmA,
PsaA, NanA, Pht-E (BVH-3), ENO, Pht-D (Sp1003), and Sp0189
were significantly higher than those in children without preceding
positive cultures at the ages of 12 and 24 months, respectively
(Table 2). In addition, SlrA IgG antibodies were higher in 12
month olds with recent pneumococcal challenge than in culture-
negative children. Calculations of immunogenicity at 24 months
in relation to proven previous colonization in the preceding 2
years showed similar data (Table 2).
We performed identical calculations for immunogenicity of S.
aureus proteins. At 12 months of age, we found significantly
higher antibody titers against S. aureus proteins ClfB and Efb in
children colonized at 6 weeks and/or 6months of age compared to
noncolonized children. At 24 months of age, we observed higher
antibody titers against ClfA and Efb (38) and also higher antibody
titers against CHIPS, LukF, and LukD in children with culture-
proven colonization at 12 and/or 18 months of age (P  0.001)
(Table 2).
Repeating the calculations, including “current” colonization
(immunogenicity at 12 months based on culture results at 6
weeks, 6months, and 12months of age and immunogenicity at 24
months based on culture results at 12, 18, and 24months), did not
change the results (Table 2).
Repeating the 24-month calculations, taking into account cul-
ture results from all sample times in the previous 2 years, showed
results similar to those taking into account culture results from the
preceding year (Table 2).
Additionally, we assessed the impact of the number of positive
cultures on antibody levels at 12 months and 24 months. Fifteen,
17, 35, 42, 29, and 7 children were positive for S. pneumoniae zero,
one, two, three, four, and five times, respectively, in the preceding
2 years (5 sample times). S. aureus was cultured zero, one, two,
three, four, and five times from 69, 57, 18, 9, 2, and 1 children 24
months of age, respectively (Table 3). We found a significant pos-
itive association between the number of cultures (0, 1, 2, and3)
positive for S. pneumoniae and S. aureus in the first 2 years of life,
and antibody titers against pneumococcal proteins PspA, PpmA,
SlrA, Sp0189, Pht-D (Sp1003), BvH3, ENO, Sp1633, NanA, PLY,
PsaA, and CbpA (P  0.003) and S. aureus proteins ClfA, Efb,
LukD, SCIN, CHIPS, HlgB, and FnbpB (P  0.001) (Table 3)
measured at 24 months of age. Similar trends were observed at 12
months of age (Table 3).
FIG 1 Dynamics of humoral responses against both pathogens in time. Pro-
teins in which significant changes were observed are depicted. (A) We ob-
served a decrease in anti-IgG levels against half the S. aureus proteins between
the ages of 12 and 24 months (P  0.001; *, P  0.004). (B) We observed an
increase in anti-IgG levels against almost all S. pneumoniae virulence factors
between the ages of 12 and 24 months (P 0.003).
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Finally, we performed a combined measurement of responses
to all proteins to reflect the overall antibody responses to the in-
dividual organisms. At both 12 months and 24 months of age, the
combined antibody response against S. pneumoniae and S. aureus
was significantly higher in children with previous culture-proven
carriage than in noncolonized children (all P values 0.002).
Protectiveness of S. pneumoniae and S. aureus antibodies.
We assessed the potential protectiveness of anti-protein anti-
bodies by relating antibody levels at 12 months to subsequent
colonization with the homologous species in the following
year. Furthermore, we also explored whether these antibodies
are protective against the heterologous species. We observed
no negative correlation between antibodies to any of the S.
pneumoniae and S. aureus proteins at the age of 12 months and
pneumococcal and/or S. aureus colonization in the following
year (data not shown).
Development of antibodies in relation to PCV7 vaccination.
To examine the effect of PCV7 on development of natural anti-
bodies to pneumococcal and S. aureus antigens, we compared
anti-IgG levels against pneumococcal and staphylococcal proteins
between children previously immunized with PCV7 and nonim-
munized children. In the 12-month-old group, serum antibodies
were measured for 76 vaccinees and 29 controls, and in the 24
month olds for 70 vaccinees and 77 controls. We observed no
significant differences in anti-protein antibodies between vaccin-
ees and controls for both pneumococcal and S. aureus antigens at
both ages. Nevertheless, we did observe a small trend toward
slightly lower pneumococcal antibody levels in the vaccinated
group for NanA (MFI, 2,982 versus 2,177 [P  0.025]), Pilus A
(MFI, 34 versus 19 [P  0.034]), PspA (MFI, 3,686 versus 1,060
[P 0.015]), and PsaA (MFI, 22,510 versus 20,281 [P 0.054]) at
24 months of age comparing the unvaccinated and the vaccinated
group, respectively.
DISCUSSION
In a search for potential future protein vaccine candidates, we
studied the immunogenicities of S. aureus and S. pneumoniae pro-
teins and the potential protective levels of these antibodies against
colonization in PCV-vaccinated and nonvaccinated infants. The
study was performed in a randomized control setting before na-
tionwide PCV7 introduction in The Netherlands. We examined
18 pneumococcal and 40 S. aureus proteins in total, including 21
S. aureus proteins that were tested for immunogenicity for the first
time. Our experiments demonstrated the presence of natural an-
TABLE 3 Anti-protein antibody levels of children in relation to S. pneumoniae and S. aureus colonization frequency
Age groupa n
No. of times
culture
positiveb
Ab (MFI)c
S. pneumoniae
PspA PpmA SlrA Sp0189 Pht-D Pht-E ENO Sp1633 NanA PLY PsaA CbpA
12 mo 31 0 107 0 0 824 1,179 111 15 1,759 94 933 6,997 654
35 1 493 603 0 3,175 10,694 3,346 75 1,949 577 4,173 16,558 17,897
28 2 1,049 1,560 221 5,662 20,041 5,330 127 2,350 1,127 6,698 22,171 22,814
11 3 593 2,850 462 6,858 23,126 8,176 146 3,321 1,195 7,856 20,579 24,668
24 mo 15 0 113 12 143 2,430 11,560 368 119 2,287 279 3,512 5,771 480
17 1 851 827 372 6,177 22,743 7,341 195 2,941 2,516 11,364 20,115 23,665
35 2 3,322 3,779 504 8,815 23,835 9,966 270 3,218 2,042 12,039 22,467 24,886
42 3 5,294 7,326 450 11,328 24,460 16,940 370 3,851 3,055 12,711 22,762 24,953
29 4 5,726 8,084 787 12,137 24,796 16,269 410 4,293 3,204 12,432 22,830 25,193
7 5 637 4,896 49 11,333 24,692 14,442 276 3,019 2,807 7,081 21,401 24,647
S. aureus
ClfA ClfB Efb LukD SCIN CHIPS HlgB FnbpB
12 mo 50 0 285 200 361 231
41 1 407 689 998 273
14 2 2,980 2,030 1,240 749
4 3 3,524 1,966 897 407
24 mo 69 0 198 229 757 407 275 1,018 135
57 1 495 610 1,590 1,966 3,117 2,771 207
18 2 884 1,344 3,482 4,037 8,877 5,154 596
9 3 2,322 6,294 8,721 6,101 11,627 6,338 964
2 4 730 3,507 1,677 3,033 2,072 1,536 4,365
1 5 5,406 10,165 7,369 13,472 13,254 11,865 916
a For S. pneumoniae, 12 mo olds, n 105; 24 mo olds, n 145 (2 out of 147 children for whom serology data were available were excluded because of missing culture data [Table
1]). For S. aureus, 12 mo olds, n 109; 24 mo olds, n 156 (2 out of 158 children for whom serology data were available were excluded because of missing culture data [Table 1]).
b Total number of times culture positive at 6 weeks and 6 and 12 months (12 mo) or at 6 weeks and 6, 12, 18, and 24 months (24 mo).
c Median antibody (Ab) levels (MFI units) against S. pneumoniae and S. aureus proteins. For the 12-month group, Kruskall-Wallis test in children 0 to2 times culture positive,
P 0.003 for S. pneumoniae and P 0.001 for S. aureus. For the 24-month group, Kruskall-Wallis test in children 0 to3 times culture positive, P 0.003 for S. pneumoniae and
P 0.001 for S. aureus.
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tibodies to all tested staphylococcal and pneumococcal proteins at
both 12 and 24 months, with increasing anti-pneumococcal anti-
bodies and declining anti-staphylococcal antibodies with age.
These findings are in line with the literature (18, 38) and corre-
spond to the natural dynamics of colonization, where nasopha-
ryngeal colonization with pneumococcus increases and staphylo-
coccal colonization decreases with age. Therefore, these data
support the hypothesis that anti-protein antibodies are a result of
natural exposure to the pathogens studied.
It is noteworthy that anti-Pilus A IgG was detectable in only
10% of the 12-month-old children but in over 80% of 24 month
olds. This might be caused by lower immunogenicity of the pro-
tein, or itmight be because the pilus is expressed in only aminority
of strains. A previous study showed that the pilus frequencymight
be reduced by the conjugate pneumococcal vaccine (28), which
was supported by our data showing a trend toward a lower anti-
body response against Pilus A in the PCV7-vaccinated group at 24
months of age.
Natural immunogenicity of many of the proteins was sup-
ported by the strong correlation between culture-proven coloni-
zation and consecutive development of antigen-specific antibod-
ies to most pneumococcal virulence factors and several S. aureus
proteins. We observed significantly higher IgG antibody levels
against the S. aureus proteins Efb and CHIPS (34, 38) and against
ClfA, ClfB, LukD, and LukF in children with culture-proven col-
onization in the preceding year(s), which underlines the immu-
nogenicity of the organism and specifically of these proteins. In-
terestingly, ClfB appears to be a major determinant of persistent
nasal S. aureus colonization in humans (37, 40). ClfA is known to
reduce opsonophagocytosis of S. aureus by neutrophils (8). Se-
creted cytolytic toxins (LukD and LukF) interfere with neutrophil
function by causing membrane damage (8). CHIPS blocks the
neutrophil chemoattractant receptors FPR-1 and C5aR (8), while
the Efb reduces neutrophil recruitment, as well as chemoattrac-
tant C5A (16). As a result, all of these proteins seem to have an
immune-suppressive function, which potentially makes them
ideal targets for vaccine development.
Known bacterial factors that contribute to pneumococcal col-
onization are, among others, CbpA, PspA, BvH-3, Hyl, and ENO
(15, 23). CbpA binds to human secretory component on a poly-
meric Ig receptor during the first stage of translocation across the
epithelium. PspA is known to prevent binding of C3 onto the
pneumococcal surface, and BvH-3 is an inhibitor of the comple-
ment system as well. In our study, these proteins appeared immu-
nogenic as well, underlining their need to be expressed at the time
of colonization. The natural immunogenicity of all the proteins
mentioned is further supported by the significant positive associ-
ation between the frequency of culture-proven colonization and
consecutive antibody titers. For SlrA andPpmA,we even observed
unmeasurable antibody titers in 12-month-old children if their
cultures were negative at all prior colonization time points. Chil-
dren who were (repetitively) culture positive in the first year had
higher titers against both proteins, which confirms previously
published results (1).
Previously, we demonstrated in the same study population
an increase in serotype-specific anti-capsular IgG antibodies in
previous carriers compared to controls for the serotypes 19F,
23F, and 6B, as well, underlining the immunogenicity of most
capsule polysaccharides (30). Since for each carrier event the
host is exposed to a single or a few capsule polysaccharides but
to many surface-associated proteins at the same time, we also
calculated a combined overall anti-protein antibody titer for
the two species separately, which confirmed strong carriage-
related general anti-protein immunity.
Our experiments show no protective effect of antibodies
against any of the proteins on colonization in the following year.
Possibly, this is caused by downregulation of protein expression
by the bacterium under immune pressure or by the limited acces-
sibility of opsonizing antibodies to proteins shielded by the cap-
sule. Moreover, systemic antibodies might not reach the bacteria
in the nasopharyngeal niche properly. The most plausible cause
might be the polymorphic nature of S. pneumoniae and, to a lesser
extent, S. aureus proteins, resulting in low cross-protectiveness of
protein-specific antibodies among strains, which might be a seri-
ous problem for their use for future vaccine development (12, 22).
Therefore, it might not be surprising that results from murine
models strongly suggest CD4 Th17-mediated immunity rather
than antibody-mediated immunity to be the primary (natural)
mechanism of protection against pneumococcal colonization, al-
though this still needs to be confirmed in humans (5, 20). Our
immunogenicity data do not suggest cross-protection of S. aureus
and S. pneumoniae anti-protein IgG against colonization with the
heterologous bacterium, either (17). Consequently, the previously
observed negative association between S. aureus and S. pneu-
moniae colonization cannot be explained by anti-protein IgG lev-
els (4, 27).
To the best of our knowledge, the effect of PCV7 on early
natural humoral responses to S. pneumoniae and S. aureus pro-
teins is not yet known. No differences in responses to S. pneu-
moniae proteins between controls and vaccinees were observed,
although we did notice a small trend toward lower pneumococcal
antibody levels in the vaccinated group against NanA, Pilus A,
PspA, and PsaA. This might be partly the consequence of the sub-
tle temporary decrease in overall pneumococcal colonization that
we observed at 18 months of age in the vaccinated group com-
pared to the controls (in this subset of children, 57% versus 73%)
or of the observed serotype replacement, both described in more
detail previously (35, 36). The latter should imply that nonvaccine
serotypes might express fewer (homologous) epitopes on their
surfaces. The study was performed well before herd effects, after
PCV7 introduction in the Dutch National Immunization Pro-
gram. As a result, in the coming years, the impact of decreased
vaccine serotype colonization and serotype replacement on natu-
ral anti-pneumococcal protein IgGs may need to be reevaluated
(35). In addition, we observed no significant differences in IgG
antibody responses against S. aureus between controls and vaccin-
ees, which might be explained by similar colonization rates ob-
served in the two groups.
Some limitations of our study need to be recognized. First, the
results are derived from a post hoc analysis. It would have been
ideal if we had sampled the children more frequently. Due to the
6-month sampling intervals in our study, we missed several colo-
nization episodes in most individuals during their first 2 years of
life, which skewed our results toward smaller effects. This is un-
derlined by the presence of anti-protein antibodies to most pro-
teins in children who remained culture negative for pneumococci
at all sample times.
The strengths of our study include the randomized controlled
and longitudinal design, which made it possible to estimate the
effect of PCV7 vaccination on natural antibody responses against
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virulence proteins in time in a controlled setting. In addition, this
is the first study simultaneously analyzing IgG responses against S.
aureus and S. pneumoniae in this large number of samples. More-
over, we corrected formultiple testing, probably resulting in lower
numbers of false-positive associations. Finally, this multiplex flu-
orescent-bead-based immunoassay allowed us to analyze the hu-
moral responses of 58 proteins simultaneously, which is highly
advantageous when working with small volumes of pediatric se-
rum samples.
In conclusion, natural anti-protein antibodies to pneumococci
and S. aureus showed an inverse correlation with age, which is in
line with colonization dynamics. Many pneumococcal and staph-
ylococcal proteins appear to be immunogenic in children under
24 months of age. In contrast, none of the anti-protein antibodies
appeared to be either protective or cross-protective against pneu-
mococcal and S. aureus colonization in the second year of life. The
consequences of these findings for protectiveness of the proteins
when used as actual vaccine candidates should be further investi-
gated.
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